<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2794-1140</journal-id>
<journal-title><![CDATA[Pharmaceutical Care España]]></journal-title>
<abbrev-journal-title><![CDATA[Pharm Care Esp.]]></abbrev-journal-title>
<issn>2794-1140</issn>
<publisher>
<publisher-name><![CDATA[Fundación Pharmaceutical Care España]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2794-11402025000101002</article-id>
<article-id pub-id-type="doi">10.60103/phc.v27.e906</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tafamidis en el tratamiento de la amiloidosis cardiaca por transtiretina: experiencia en un paciente anciano]]></article-title>
<article-title xml:lang="en"><![CDATA[Tafamidis in the Treatment of Transthyretin Cardiac Amyloidosis: Experience in an Elderly Patient]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[María Ligros]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Piquer]]></surname>
<given-names><![CDATA[Raquel Gracia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Andujar]]></surname>
<given-names><![CDATA[Nuria Labrador]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Alejandro González]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Obispo Polanco Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Teruel ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>27</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2794-11402025000101002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2794-11402025000101002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2794-11402025000101002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La amiloidosis cardiaca por transtiretina (AC-ATTR) es una miocardiopatía rara, que se presenta en dos formas: hereditaria y no hereditaria o wild-type (frecuente en mayores de 70 años). Esta condición favorece el desarrollo de insuficiencia cardíaca progresiva y arritmias. El diagnóstico se basa en una combinación de ecocardiografía, resonancia magnética y gammagrafía, apoyado por estudios genéticos y de inmunofijación. Se presenta un caso clínico de un hombre de 80 años con antecedentes familiares de enfermedades cardíacas, que fue diagnosticado de AC-ATTR mediante estos métodos. Tras iniciar tratamiento con tafamidis (estabilizador de TTR), mostró una mejora significativa en su función cardíaca y calidad de vida. Este caso subraya la importancia del diagnóstico precoz y un enfoque terapéutico multidisciplinar para mejorar el pronóstico de los pacientes con AC-ATTR.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Transthyretin cardiac amyloidosis (ATTR-CA) is a rare cardiomyopathy that presents in two forms: hereditary and no hereditary or wild-type (commonly seen in individuals over 70 years of age). This condition leads to progressive heart failure and arrhythmias. Diagnosis is based on a combination of echocardiography, cardiac magnetic resonance imaging, and scintigraphy, supported by genetic and immunofixation studies. We present the case of an 80-year-old man with a family history of heart disease who was diagnosed with ATTR-CA through these diagnostic methods. After initiating treatment with tafamidis (a TTR stabilizer), he showed significant improvement in cardiac function and quality of life. This case highlights the importance of early diagnosis and a multidisciplinary therapeutic approach to improve the prognosis of patients with ATTR-CA.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[amiloidosis]]></kwd>
<kwd lng="es"><![CDATA[proteína TTR]]></kwd>
<kwd lng="es"><![CDATA[insuficiencia cardiaca]]></kwd>
<kwd lng="es"><![CDATA[tafamidis]]></kwd>
<kwd lng="en"><![CDATA[Amyloidosis]]></kwd>
<kwd lng="en"><![CDATA[TTR protein]]></kwd>
<kwd lng="en"><![CDATA[heart failure]]></kwd>
<kwd lng="en"><![CDATA[tafamidis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Informe de Posicionamiento Terapéutico de tafamidis (Vyndaqel®) en el tratamiento de la amiloidosis cardiaca por transtiretina en pacientes adultos (ATTR-CM)]]></source>
<year>2022</year>
<publisher-name><![CDATA[Ministerio de Sanidad]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Combarro-Eiriz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González-López]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Naharro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barge-Caballero]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización en el abordaje diagnóstico y terapéutico de la amiloidosis cardiaca por transtirretina]]></article-title>
<source><![CDATA[Rec cardio clinics]]></source>
<year>2022</year>
<volume>57</volume>
<numero>S2</numero>
<issue>S2</issue>
<page-range>S19-27</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>European Society of Cardiology</collab>
<article-title xml:lang=""><![CDATA[Guidelines for the diagnosis and treatment of acute and chronic heart failure]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2021</year>
<volume>42</volume>
<page-range>3599-726</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zahra]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Transthyretin Amyloid Cardiomyopathy (ATTR-CM)]]></source>
<year>2023</year>
<publisher-name><![CDATA[StatPearls]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Pavía]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rapezzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2021</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
